• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Turkey·Basic Materials·HEKTS.IS
Share

Hektas Ticaret T.A.S. Stocks

TRY 2.19Last Updated 09.10.2026

Issuer Rating

3/7
Performance

Modest

Risk

Considerable

Recommendation

Sell

Market Cap

TRY 374.59M

TRY 2.19
Key Takeaways

Risk factor

Weak & very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Hektas Ticaret T.A.S., founded in 1956 and headquartered in Gebze, Turkey, is a leading Turkish company that manufactures, imports, and distributes a wide spectrum of agricultural and veterinary products. For the agricultural sector, their offerings include an extensive range of crop protection solutions such as fungicides, herbicides, insecticides, acaricides, biological insecticides, fumigants, nematicides, soil fumigants, and plant growth regulators. They also provide specialized winter care treatments, summer oils, and spreading agents. Furthermore, Hektas supplies various fertilizers, including foliar applications, organo-mineral compounds, and drip irrigation products, alongside other farming essentials and even tomato seeds. In the animal health domain, the company offers a diverse portfolio of veterinary pharmaceuticals, encompassing antibacterials, vitamin and mineral supplements, feed additives, anti-inflammatory drugs, and anti-parasitics. Their product line additionally features poultry health remedies, pet care items, and pet food.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is 'expensive' on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Very favourable
7/7

The average target price of HEKTS.IS is 4.30 and suggests 96.3% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.10.2026 21:40

Delta has postponed the launch of flights to Saudi Arabia due to Houthi attacks on airports

12.10.2026 20:43

One of the world's largest gold buyers is shifting to selling gold

12.10.2026 19:22

A Crisis-Proof Formula for Shaping the Future: Why the Nobel Prize in Economics Was Awarded

12.10.2026 19:20

Is it time to buy stocks? Goldman Sachs has upgraded its recommendation for the next three months

12.10.2026 18:58

Oppenheimer upgrades Fastly to ‘outperform’ ahead of 3Q earnings and GTA VI launch

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026